Injectable Composition For Drug Delivery Using Poly Ortho Ester Polymer
Summary
USPTO published patent application US20260096985A1 for an injectable drug delivery composition using poly ortho ester (POE) polymer. The composition includes one or more solvents and therapeutic agents, including a basic therapeutic agent, with the POE polymer having a glass transition temperature between approximately −10°C and 110°C per ASTM E1640-18. Inventors are Vijay Gyanani and Jeffrey Haley, with European Application No. 19348865 filed October 3, 2025.
What changed
USPTO published a patent application for an injectable drug delivery composition utilizing poly ortho ester (POE) polymer as a carrier matrix for therapeutic agents. The claimed invention specifies a POE polymer with a glass transition temperature range of −10°C to 110°C, combined with solvents and basic therapeutic agents for controlled drug release.
This patent application may be relevant to pharmaceutical manufacturers developing injectable drug formulations, particularly extended-release or controlled-release delivery systems. Third parties should monitor this application for potential freedom-to-operate implications if developing similar injectable compositions. The publication does not grant any enforceable patent rights; enforceable rights attach only upon issuance of a granted patent after examination.
What to do next
- Monitor for USPTO examination updates
- Respond to any USPTO office actions within prescribed deadlines
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Injectable Composition For Drug Delivery
Application US20260096985A1 Kind: A1 Apr 09, 2026
Inventors
Vijay Gyanani, Jeffrey Haley
Abstract
An injectable composition for delivering a therapeutic agent is provided. The injectable composition includes one or more polymers including a poly ortho ester (POE) polymer. The POE polymer has a Tg of between about −10° C. and 110° C. as determined in accordance with ASTM E1640-18. The injectable composition also includes one or more solvents and one or more therapeutic agents. The one or more therapeutic agents includes a basic therapeutic agent. Methods for treating a condition in a patient are also provided.
CPC Classifications
A61K 9/0024 A61K 31/499 A61K 31/4995 A61K 31/519 A61K 31/551 A61K 31/554 A61K 47/34
Filing Date
2025-10-03
Application No.
19348865
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.